CClinicalTrials.gg
Status unknownNCT04691453QMBCHECCUpdated Dec 31, 2020

QM-B and QM-C Hysterectomy for Early Cervical Cancer

An interventional study of QM-C Hysterectomy and QM-B Hysterectomy in Uterine Cervical Neoplasms, sponsored by Southern Medical University, China. Status unknown at 1 site in China. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2020-12-31.

Sponsored by Southern Medical University, China · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
538
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

The goal of this clinical research study is to compare the long-term outcomes and safety of Querleu-Morrow-B(QM-B) and Querleu-Morrow-C(QM-C) hysterectomy for early cervical cancer. In this study, the surgical approach for QM-B and QM-C hysterectomy will be abdominal.

Read the detailed description

Primary Objective:

To compare 5-year overall survival and 5-year disease-free survival amongst patients who undergo a QM-B hysterectomy versus those who undergo a QM-C hysterectomy for early stage cervical cancer.

Secondary Objectives:

Compare operation time between arms. Compare blood loss between arms. Compare blood transfusion between arms. Compare intraoperative complications between arms. Compare postoperative complications between arms. Compare quality of lifes between arms.

02

Conditions studied

  • Uterine Cervical Neoplasms

Keywords

  • Cervical cancer
  • QM-B
  • QM-C
  • Oncology outcome
  • Safety
  • Hysterectomy
  • Radical Hysterectomy
  • Abdominal
03

In context

Uterine Cervical Neoplasms

1,879 studies on the registry are indexed under Uterine Cervical Neoplasms; 565 are open to participants now.

This study's planned enrollment of 538 is above the median of 100 across 1,375 interventional studies indexed under Uterine Cervical Neoplasms.

Browse Uterine Cervical Neoplasms studies →

Lead sponsor

Southern Medical University, China is the lead sponsor of 31 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • Patients who have signed an approved Informed Consent
  • 18.5≤BMI\<28
  • Histologically confirmed primary adenocarcinoma, squamous cell carcinoma or adenosquamous carcinoma of the uterine cervix;
  • Patients with Histologically confirmed stage IA1 (with lymph vascular invasion), stage IA2, stage IB1, stage IB2, or stage IIA1 disease(FIGO 2018).
  • Eastern Cooperative Oncology Group(ECOG) Performance Status of 0 or 1.
  • Patients undergoing the Non-Fertility-Sparing surgery.
  • Patients undergoing abdominal surgery.

Exclusion criteria

Exclusion Criteria:

  • The life expectancy of the patient is less than 6 months.
  • Patients with serious medical diseases.
  • Patients with contraindications to surgery or anesthesia.
  • Preoperative imaging studies suggest metastasis to pelvic lymph nodes or para-aortic lymph nodes.
  • Patient asks to preserve fertility.
  • The patient requested direct radiation therapy.
  • Patients with adjuvant radiotherapy or chemotherapy before surgery.
  • Patients judged by the investigator to be unsuitable to participate in this trial.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
538 participants (estimated)

Study arms

  • Active comparator
    QM-C Hysterectomy

    QM-C Hysterectomy

    Procedure: QM-C Hysterectomy

  • Experimental
    QM-B Hysterectomy

    QM-B Hysterectomy

    Procedure: QM-B Hysterectomy

Interventions

  • ProcedureQM-C Hysterectomy

    This operation corresponds to the classical radical hysterectomy. The lateral border is defined as the medial aspect of the internal iliac artery and vein. Transection of the rectovaginal and rectouterine ligaments is performed at the rectum. Transection of the ventral parametrium ligament is performed at the bladder. Both the vesicouterine and vesicovaginal ligaments are resected. The ureter is completely mobilized and lateralized. The length of the vaginal cuff is adjusted to the vaginal extent of the tumor.

    Also known as: Type III radical hysterectomy, Radical hysterectomy, Type C radical hysterectomy

  • ProcedureQM-B Hysterectomy

    Type B is the modified radical hysterectomy. The ureter is unroofed and mobilized laterally, permitting transection of the paracervix at the level of the ureteral tunnel. Partial resection of the uterosacral peritoneal fold of the rectouterine ligament (dorsal parametrium) and the vesicouterine (ventral parametrium) ligament also is a standard component of this resection. Approximately 10 mm of the vagina from the caudal edge of the cervix or tumor is resected, without intent to radically resect the paravaginal tissues.

    Also known as: Type II radical hysterectomy, Modified radical hysterectomy, Type B radical hysterectomy

06

What researchers measure

Primary outcomes

  1. Rate of overall survival

    Compare treatment equivalence

    Time frame: 5 years from surgery

  2. Rate of disease-free survival

    Compare treatment equivalence

    Time frame: 5 years from surgery

Secondary outcomes

  1. Operation time

    Compare operation time between groups by timer

    Time frame: Intra-operatively

  2. Volume of blood loss

    Compare blood loss between groups by assessment

    Time frame: Intra-operatively

  3. Rate of blood transfusion

    Compare rate of blood transfusion between groups

    Time frame: Intra-operatively

  4. Rate of intraoperative complications

    Compare intraoperative complications between groups

    Time frame: Intra-operatively

  5. Rate of postoperative complications

    Compare postoperative complications between groups

    Time frame: 6 months from surgery

  6. Quality of life Questionnaires

    Compare quality of lifes between groups by questionnaire: EORTC CX24. EORTC CX24 for symptom experience, body imageand sexual/vaginal functioning. The scores of EORTC CX24 range from 0 to 100; a higher score represents a higher ("better") level of functioning, or a higher ("worse") level of symptoms.

    Time frame: 6 months from surgery

  7. Pelvic Floor Distress Inventory Questionnaire

    Compare PFDI between groups by questionnaire PFDI-20. The calculation of the total scores of PFDI-20 range from 0 to 300; the higher the score the greater the perceived impact that pelvic floor dysfuntion has on a patient's life.

    Time frame: 5 years from surgery

  8. Costs

    Compare costs between groups

    Time frame: 6 months from surgery

07

Study locations

1 of 1 sites recruiting
  • Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, No. 1838, Guangzhou Avenue, Guangzhou 510515
    Guangzhou, Guangdong 510515, China
    • Chunlin Chen, Doctor · Contact · jieru@163.com · 8602062787562
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Dec 31, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04691453
Lead sponsor
Southern Medical University, China
Responsible party
Chen Chunlin (Director, Head of Obstetrics and Gynecology, Principal Investigator, Clinical Professor, Southern Medical University, China) — Principal investigator
First posted
Dec 31, 2020
Start date
Jan 1, 2021 (estimated)
Primary completion
Jan 1, 2025 (estimated)
Completion
Jan 1, 2025 (estimated)
Last update
Dec 31, 2020

Study contacts

Chunlin Chen, Doctor
Contact
jieru@163.com
008613725263051
Chunlin Chen, Doctor
study chair · Nanfang Hospital, Southern Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion